glp-1 shortage news today november 2025 The class of medicines known as GLP-1s have transformed clinical practice and shifted public perception to view obesity as a chronic disease that merits medical management. Growing research is demonstrating that the GLP-1 Weight Loss Drug Enforcement

Ascendis Pharma A/S granted Novo Nordisk A/S exclusive global rights to its TransCon technology for the development, manufacturing, and commercialisation of Novo Nordisk products aimed at metabolic diseases, including obesity and type 2 diabetes, along with select cardiovascular applications

Healthcare providers need to overcome barriers related to the shortage and mitigate undesired negative consequences from an inability of patients with type 2 diabetes mellitus to obtain GLP-1 receptor agonist therapies amid this global access challenge

Incomplete reduction of oxygen in hypoxic condition results in elevated production of superoxide and hydroxyl radicals

Tesamorelin should not be used in children with open epiphyses, among whom excess GH and IGF-1 may result in linear growth acceleration and excessive growth

It is not peer-reviewed, it is not laboratory data, and it should not appear in a methods section or a literature review